Recent Updates
Recently added Catalysts
COLL

Collegium to Present at Upcoming Investor Conferences

Key Takeaway: CANTON, Mass., May 23, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in June: The Jefferies 2017 Global Healthcare Conference on Tuesday, June 6th at 9:00 a.m. ET in New Yo

Full Press Release Details

CANTON, Mass., May 23, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in June:
The Jefferies 2017 Global Healthcare Conference on Tuesday, June 6th at 9:00 a.m. ET in New York City
The 37th Annual William Blair Growth Stock Conference on Wednesday, June 14th at 2:40 p.m. CT at The Four Seasons Hotel Chicago
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Contact Data

Contact

With a Reader Account, it's easy to send email directly to the contact for this release. Sign up today for your free Reader Account!
Already have an account? Log in here.
Last updated: May 23, 2017